CEO Edward Pershing Buys $100K in Convertible Preferred Stock
PVCT is trading near its 52-week low of $0.038 (13% above the low).
Summary
Provectus Biopharmaceuticals' CEO, Edward Pershing, made a significant open market purchase of $99,998 in Series D-1 Convertible Preferred Stock, signaling strong insider confidence.
Key Events · Ownership and Investor Activity · PVCT
-
CEO Purchases Convertible Preferred Stock
Edward Pershing, CEO and Director, acquired $99,998 worth of Series D-1 Convertible Preferred Stock in an open market transaction on February 9, 2026.
-
Significant Insider Confidence
This purchase represents over 0.5% of the company's market capitalization, indicating strong conviction from a key executive in this nano-cap company.
-
Strategic Capital Alignment
The purchase of convertible preferred stock follows a recent amendment to preferred stock terms on February 2, 2026, aligning with the company's capital structure strategy.
Analysis · PVCT · Life Sciences
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, has demonstrated significant confidence in the company by purchasing $99,998 worth of Series D-1 Convertible Preferred Stock. This transaction, representing over 0.5% of the company's market capitalization, is a substantial insider buy, especially for a nano-cap company. The purchase of convertible preferred stock, which can convert into common stock at a 1:10 ratio, indicates a long-term bullish outlook from a key executive. This follows a recent 8-K filing on February 2, 2026, where the company amended its preferred stock terms, suggesting a strategic alignment with capital structure adjustments.
At the time of this filing, PVCT was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $18.1M. The 52-week trading range was $0.04 to $0.11. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.